Saturday 17 October 2026
Export KLRS’s income statement to Excel — free account
Kalaris Therapeutics Inc.
KLRS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 21.3% and free cash flow grew 11.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.00
0.19
−8.68%
Follow KLRS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(68.06%) | 488.01% | (66.60%) | (79.91%) | |
| (54.46%) | (67.93%) | (41.43%) | (46.02%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(76.91%) | (39.82%) | (48.79%) | (50.77%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.10) | (2.50) | (1.79) | (1.72) | |
Free Cash Flow |
(39.30) | (38.23) | (42.51) | (41.02) | |
Capital Expenditures |
(0.13) | 0.14 | — | — | |
| Other line items | |||||
Cash ROIC |
(33.06%) | (19.43%) | (25.64%) | (27.13%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.71 | 0.88 | 0.96 | 0.93 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.58) | (0.86) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.09) | (2.51) | (1.79) | (1.72) | |
Capex per Share |
(0.01) | 0.01 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates